Postformulation peptide drug loading of nanostructures

Hua Pan, Jon N. Marsh, Eric T. Christenson, Neelesh R. Soman, Olena Ivashyna, Gregory M. Lanza, Paul H. Schlesinger, Samuel A. Wickline

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

19 Scopus citations

Abstract

Cytolytic peptides have commanded attention for their anticancer potential because the membrane-disrupting function that produces cell death is less likely to be overcome by resistant mutations. Congruently, peptides that are involved in molecular recognition and biological activities become attractive therapeutic candidates because of their high specificity, better affinity, reduced immunogenicity, and reduced off target toxicity. However, problems of inadequate delivery, rapid deactivation in vivo, and poor bioavailability have limited clinical application. Therefore, peptide drug development for clinical use requires an appropriate combination of an effective therapeutic peptide and a robust delivery methodology. In this chapter, we describe methods for the postformulation insertion of peptide drugs into lipidic nanostructures, the physical characterization of peptide-nanostructure complexes, and the evaluation of their therapeutic effectiveness both in vitro and in vivo.

Original languageEnglish
Title of host publicationMethods in Enzymology
PublisherAcademic Press Inc.
Pages17-39
Number of pages23
DOIs
StatePublished - 2012

Publication series

NameMethods in Enzymology
Volume508
ISSN (Print)0076-6879
ISSN (Electronic)1557-7988

Keywords

  • Liposomes
  • Melittin
  • NF-kB signaling pathway
  • Nanoparticles
  • Peptide drug delivery
  • Postformulation
  • Targeted therapy

Fingerprint Dive into the research topics of 'Postformulation peptide drug loading of nanostructures'. Together they form a unique fingerprint.

Cite this